In Group A, the ORR was 33% and the disease control rate (DCR) was 55.6%, and the ORR was 50% with a DCR of 83% in Group B. Furthermore, it was observed that IMP321 could promote a sustained increase in CD8+ and CD4+ T cells within the tumor microenvironment by activating dendritic cells (DCs), thereby enhancing tumor immune surveillance (69). Here, CD4 is linked to neoplasm.